|
|
Cimzia - Newsfeeds
-
-
TNF blocker medications include Remicade (infliximab; Centocor Ortho Biotech ), Enbrel (etancercept; Amgen ), Humira (adalimumab; Abbott ), Cimzia (certolizumab pegol; UCB ) and Simponi (golimumab; Centocor Ortho Biotech ). While the majority of cases of ...
-
-
April 14, 2011 — The US Food and Drug Administration (FDA) continues to receive reports of hepatosplenic T-cell lymphoma (HSTCL) in adolescents and young adults treated with tumor necrosis factor (TNF) blockers, azathioprine, and/or mercaptopurine, the ...
-
-
The numbers are being updated by the FDA. The TNF-blocking drugs include etanercept (Enbrel), infliximab (Remicade), adalimumab (Humira), certolizumab pegol (Cimzia), and golimumab (Simponi). Most cases have occurred in patients receiving one of these ...
-
-
The FDA has approved Actemra (tocilizumab; Genentech ), given alone or in combination with methotrexate, for the treatment of active systemic juvenile idiopathic arthritis (SJIA), or Still's disease, in children =2 years. This approval was based on data ...
-
-
The number of people treated in U.S. hospitals for illnesses and injuries from taking medicines jumped 52 percent between 2004 and 2008 - from 1.2 million to 1.9 million - according to the latest News and Numbers from the Agency for Healthcare Research and ...
-
-
The numbers are being updated by the FDA. The TNF-blocking drugs include etanercept (Enbrel), infliximab (Remicade), adalimumab (Humira), certolizumab pegol (Cimzia), and golimumab (Simponi). Most cases have occurred in patients receiving one of these ...
-
-
They include such widely used products as Merck & Co Inc's and Johnson & Johnson's Remicade and Simponi, Amgen Inc's Enbrel, Abbott Laboratories Inc's Humira and UCB SA's Cimzia. The Food and Drug Administration has previously warned of an increased risk ...
-
-
PK) Cimzia. The newly invigorated competition could lead to a slowdown in Humira’s market share gains. Meanwhile, Abbott’s Kaletra faces intense competition in the HIV market from players like Gilead Sciences ( GILD ), Bristol-Myers Squibb ( BMY ), and ...
-
-
Abbott Laboratories (NYSE: ABT - News ) is all set to announce its first quarter 2011 results on April 20, 2011 before the opening bell. The Zacks Consensus Estimate for the first quarter of 2011 is $0.90, representing a year-over-year increase of 11.1% ...
-
-
Six-and-a-half weeks after receiving the first hand transplant in the western United States, Emily Fennell is becoming so accustomed to her new right hand that she barely remembers when she didn't have one. The 26-year-old from Yuba City, Calif., underwent ...
-
-
FDA green-lighted the humanized anti-IL-6 receptor mAb in individuals who have not responded to TNF- a inhibitors, such as Brussels-based UCB's Cimzia (certolizumab pegol), New York–based Pfizer's and Amgen's Enbrel (etanercept), Abbott Park ...
-
-
The Spondylitis Association of America's (SAA) online Screening Tool for Ankylosing Spondylitis was featured in a news story on ABCNews.com on March 8. Ankylosing spondylitis (AS) is a crippling form of arthritis that generally strikes young people in ...
-
-
Patients with earlier stage high-risk Chronic Lymphocytic Leukemia (CLL) recently began receiving a new combination treatment in a Phase I/II clinical trial that researchers believe could result in a more effective therapy for this disease, Biothera ...
-
-
The company also licenses its PEGylation platform for various products, such as PEG-INTRON, Macugen, and CIMZIA. Enzon Pharmaceuticals, Inc. was founded in 1981 and is based in Bridgewater, New Jersey. UNITED SECURITY BANCSHARES (NASDAQ:USBI) - United ...
-
-
For adult patients not currently on immediate-release VIRAMUNE , a 14-day lead-in dose of 200 mg immediate-release VIRAMUNE , once-daily, is necessary prior to taking VIRAMUNE XR once-daily because it has been demonstrated to reduce the frequency of rash ...
-
-
MabVax Therapeutics, Inc., a privately held clinical stage biotechnology company focused on the development of vaccine and antibody based therapies to address the unmet medical need of preventing recurrent cancer , announces that it has received the Phase ...
-
-
The companys partnered product portfolio also comprises Neulasta for neutropenia; PEGASYS for Hepatitis-C; Somavert for Acromegaly; PEG-INTRON for Hepatitis-C; Macugen for age-related macular degeneration; CIMZIA for Crohn's disease; MIRCERA for renal ...
-
-
In 2011, the state-of-the-art treatment of RA is dramatically different. The paradigm of therapy worldwide now is early, aggressive therapy with the goal being remission or the lowest disease activity state possible, maintained for the longest time period ...
-
-
Significant advances in our understanding of RA and its management have been made in the past decade, resulting in earlier intervention with biologic DMARDs, particularly in patients with evidence of aggressive, erosive disease. Here, one such biologic ...
-
-
These include adalimumab, etanercept, infliximab and certolizumab pegol. It said it also recommends rituximab for patients who haven't responded well to at least one tumor-necrosis-factor, or TNF, inhibitor. For those who can't take rituximab following an ...
Content provided by MSN. LegalView is not responsible for the accuracy of the information provided above.
Pages:
1
2
3
4
5
6
...
Next
|
|
